Clinical Trials - HIV/Aids - Current studies

HIV/Aids research seeks cure and to reduce disease burden

CHRU is a major resource for HIV/Aids research, treatment, care and educating communities. The Unit plays a key role in finding a cure for HIV infection and in reducing the burden of disease due to HIV infection and its complications, including tuberculosis and viral hepatitis.

Our current clinical trials in HIV/Aids are listed here:

NCT03070223
This study, also known as the Reprieve trial, aims to prevent vascular events in HIV. It looks at cardiovascular risk in HIV positive patients who are living longer but developing other issues such as increased vascular risk. The study’s main aim is to determine the effects of pitavastatin as a primary prevention strategy for major adverse cardiovascular events in HIV.

Principal Investigator (PI) Interventional / Observational Closed/ Ongoing Start/
end date
Network Funders/ sponsors
Dr Badal-Faesen Interventional Enrolling 2016
    AIDS Clinical Trials Group (ACTG)
National Institution of Health and Research

NCT00867048
The Strategic Timing of Antiretroviral Treatment (START) study has been instrumental in changing the guidelines with regards to when to start treatment. It has already found that patients should start ART regardless of their CD4 count. It has laid foundations for the test and treat approach. It has also shown that HIV-infected individuals have a lower risk of developing AIDS and other illnesses if they start taking ARVs sooner, instead of waiting until the CD4+ cell count drops to lower levels. These findings support offering treatment to everyone with HIV. This study is focused on establishing whether earlier ART would prevent morbidity and mortality in HIV, and to establish the correct time to start ARVs.

PI Interventional / Observational Closed/ Ongoing Start/

end date

Network Funders/ sponsors
Dr Badal-Faesen Interventional Ongoing 2011/current International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) National Institution of Health and Research

NCT03512210

A single-arm study to evaluate the feasibility and efficacy of a minimal monitoring strategy to deliver pan-genotypic Ribavirin-free HCV therapy to HCV infected populations who are HCV treatment naïve with evidence of active HCV infection. It is also called the MINMON Study.

Principal Investigator (PI) Interventional / Observational Closed/ Ongoing Start/
end date
Network Funders/ sponsors
Dr Jaclyn Bennet Interventional Enrolling Sept 18
    AIDS Clinical Trials Group (ACTG)
National Institutes of Health (NIH)

NCT02519777

A randomized, double-blinded, placebo-controlled trial comparing antiretroviral intensification with maraviroc and dolutegravir with no intensification or intensification with dolutegravir alone for the treatment of cognitive impairment in HIV.

Principal Investigator (PI) Interventional / Observational Closed/ Ongoing Start/
end date
Network Funders/ sponsors
Dr Thando Mwelase Interventional Follow Up Aug 18
    AIDS Clinical Trials Group (ACTG)
National Institutes of Health (NIH)

NCT02403674

Protocol number title: Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021)

PI Interventional / Observational Closed/ Ongoing Start/
end date
Commercial Funders/ sponsors
Dr Rassool Interventional Ongoing Merck/ MSD

NCT02652260

Protocol number title: Effects of Switching From ATRIPLA^TM (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

Principal Investigator (PI) Interventional / Observational Closed/ Ongoing Start/
end date
Commercial Funders/ sponsors
Dr Nureen Jina Interventional Ongoing Start – Sept 2017 Merck/ MSD